Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

To define the involvement of p16/CDKN2 and p15/MTS2 tumor‐suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis‐diamminedichloroplatinum (...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2002-06, Vol.99 (4), p.579-582
Main Authors: Kudoh, Kazuya, Ichikawa, Yoshihito, Yoshida, Sadao, Hirai, Misako, Kikuchi, Yoshihiro, Nagata, Ichiro, Miwa, Masanao, Uchida, Kazuhiko
Format: Article
Language:English
Subjects:
Adult
Antineoplastic agents
Biological and medical sciences
Cell Cycle Proteins - genetics
Chemotherapy
Cisplatin - therapeutic use
Cyclin-Dependent Kinase Inhibitor p15
Cyclin-Dependent Kinase Inhibitor p16 - genetics
Female
Female genital diseases
Gene Deletion
Genes, p16
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
ovarian cancer
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - genetics
p15/MTS2
p16/CDKN2
Pharmacology. Drug treatments
Polymerase Chain Reaction
Prognosis
Time Factors
Treatment Outcome
Tumor Suppressor Proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To define the involvement of p16/CDKN2 and p15/MTS2 tumor‐suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis‐diamminedichloroplatinum (II) (cisplatin)‐based combination chemotherapy. Homozygous deletion of p16/CDKN2 and p15/MTS2 genes was found in 8 (18%) and 15 (33%) cases, respectively. Response to the chemotherapy was confirmed by finding at second surgery after the chemotherapy in 26 patients, resulting in 17 responders and 9 nonresponders. The abundance of gene deletion in nonresponders (56%) was significantly higher (p = 0.0463) when compared to that in responders (18%). Moreover, the deletion of genes was a significant poor prognostic factor (p = 0.0441) in advanced ovarian cancer. These results suggest that deletion of p16/CDKN2 and/or p15/MTS2 is a potential indicator for poor chemotherapy response and adverse prognosis in ovarian cancer patients. © 2002 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.10331